46 results on '"Maria Luisa Montes"'
Search Results
2. Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study
- Author
-
Salgado, Maria, primary, Gálvez, Cristina, additional, Nijhuis, Monique, additional, Kwon, Mi, additional, Cardozo-Ojeda, E Fabian, additional, Badiola, Jon, additional, Gorman, Matthew J, additional, Huyveneers, Laura E P, additional, Urrea, Victor, additional, Bandera, Alessandra, additional, Jensen, Björn-Erik Ole, additional, Vandekerckhove, Linos, additional, Jurado, Manuel, additional, Raj, Kavita, additional, Schulze zur Wiesch, Julian, additional, Bailén, Rebeca, additional, Eberhard, Johanna M, additional, Nabergoj, Mitja, additional, Hütter, Gero, additional, Saldaña-Moreno, Raquel, additional, Oldford, Sharon, additional, Barrett, Lisa, additional, Ramirez, Maria Luisa Montes, additional, Garba, Salisu, additional, Gupta, Ravi Kumar, additional, Revollo, Boris, additional, Ferra-Coll, Christelle, additional, Kuball, Jurgen, additional, Alter, Galit, additional, Sáez-Cirión, Asier, additional, Diez-Martin, Jose Luis, additional, Duke, Elizabeth R, additional, Schiffer, Joshua T, additional, Wensing, Annemarie, additional, Martinez-Picado, Javier, additional, Muscatello, Antonio, additional, Calmy, Alexandra, additional, Chapel, Anais, additional, Mamez, Anne-Claire, additional, Passaes, Caroline, additional, Brisseau, Clarissa, additional, Olivarria, Eduardo, additional, Knops, Elena, additional, Heger, Eva, additional, Bikhezar, Fatima, additional, Perdomo-Celis, Federico, additional, Kobbe, Guido, additional, Gabriel, Ian H, additional, Lunzen, Jan V, additional, Dalmau, Judith, additional, Martín-Carbonero, Luz, additional, Puertas, Mari Carmen, additional, Garcia-Guerrero, Mari Carmen, additional, de Scheerder, Marie-Angélique, additional, Angin, Mathieu, additional, Lübke, Nadine, additional, Balsalobre, Pascual, additional, de Paz, Raquel, additional, Kaiser, Rolf, additional, Kerre, Tessa, additional, Harrer, Thomas, additional, Luedde, Tom, additional, and Rocha, Vanderson, additional
- Published
- 2024
- Full Text
- View/download PDF
3. Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
- Author
-
Rafael Micán, Alejandro de Gea Grela, Julen Cadiñanos, Rosa de Miguel, Carmen Busca, Jose I. Bernardino, Eulalia Valencia, Maria Luisa Montes, Rocío Montejano, Victoria Moreno, Ignacio Pérez Valero, Lucía Serrano, Juan González-García, Jose R. Arribas, and Luz Martín-Carbonero
- Subjects
Male ,Anti-HIV Agents ,Adenine ,Immunology ,HIV Infections ,Heterocyclic Compounds, 4 or More Rings ,Drug Combinations ,Infectious Diseases ,HIV-1 ,Humans ,Reverse Transcriptase Inhibitors ,Emtricitabine ,RNA ,Immunology and Allergy ,Female ,Tenofovir - Abstract
Few clinical trials and cohort studies have evaluated the efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with HIV (PWH) with preexisting M184V/I or other nucleos(t)ide reverse transcriptase inhibitor (NRTI) resistance-associated mutations (RAMs). Real-world data are also scarce.Retrospective review of treatment-experienced patients who started B/F/TAF in a cohort of PWH. HIV-RNA less than 50 copies/ml was analyzed at 48 weeks in an intention-to-treat (ITT) analysis (missing=failure) and per protocol analysis (patients with missing data or changes for reasons other than virological failure were excluded). Results were compared in patients with and without previous NRTI-RAMs.Five hundred and six PWH were included (16.2% women). Median age and time with HIV infection were 52.3 and 18.9 years, respectively. At baseline, viral load was less than 50 copies/ml in 440 patients (86.6%). Overall, 69 (13.6%) participants had documented preexisting NRTI-RAMs: 57 (11.2%) M184V/I and 30 (5.9%) tenofovir RAMs. In the ITT analysis, 83% (420/506) had HIV-RNA less than 50 copies/ml [82.2% (359/437) and 88.4% (61/69) in persons without and with NRTI-RAMs, respectively ( P = 0.2)]. In the per protocol analysis 94.2% (420/445) had HIV-RNA less than 50 copies/ml [94.4% (359/380) vs. 93.8% (61/65); P = 0.2]. A total of 61 participants were excluded from the per protocol analysis (23 missing data, 19 discontinued B/F/TAF because of toxicity, 13 for other reasons, and 6 died).Switching to B/F/TAF is well tolerated and effective in the real-world setting, even in patients with preexisting NRTI RAMs, such as M184V and RAMs conferring resistance to tenofovir. These results confirm the robustness of this combination.
- Published
- 2022
4. Benefits of rilpivirine for liver stiffness in HIV/HCV-coinfected patients
- Author
-
Carmen Busca Arenzana, Juan González-García, Ana Blas-García, Juan V. Esplugues, Antonio Olveira Martín, and Maria Luisa Montes Ramírez
- Subjects
Microbiology (medical) ,General Medicine - Published
- 2022
5. Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study
- Author
-
Alejandro D. Bendala‐Estrada, Mariana Diaz‐Almiron, Carmen Busca, Rafael Mican, Julen Cadiñanos, Maria Luisa Montes, Luz Martin‐Carbonero, Eulalia Valencia, Rocío Montejano, Ana Delgado‐Hierro, and Jose I. Bernardino
- Subjects
Infectious Diseases ,Health Policy ,Pharmacology (medical) - Abstract
The use of tenofovir alafenamide (TAF) has been associated with increased cholesterol and body weight. Real-life data on the metabolic effects of switching from a TAF-based triple regimen to a dolutegravir (DTG)-based two-drug regimen (2-DR) are scarce.A retrospective cohort study of patients who have switched from a triple TAF-based regimen to a 2-DR [DTG-lamivudine (DTG-3TC) or DTG- rilpivirine (DTG-RPV]) with at least 6 months of follow-up. The primary endpoint was the absolute change in lipid fractions at 6 months. Secondary outcomes were percentage changes in lipid fraction, effectiveness and safety at 6 and 12 months [intention to treat (ITT), missing = failures].A total of 118 patients (87 on DTG-3TC, 31 on DTG-RPV) were included. Median age was 51 years (interquartile range: 43-59), 86% were male, CD4 T-cell count was 692 cells/μL, and 98% viral load (VL) 50 copies/mL. At 6 months there was a decrease in total and low-density lipoprotein cholesterol of 10.7 mg/dL [95% confidence interval (CI): 2.2-19.1; p ≤ 0.001] and 8.3 mg/dL (95% CI: 0.74-15.9; p = 0.026), respectively. There was a reduction in cardiovascular risk from 4.5% at baseline to 4% at 12 months (p = 0.040). Virological effectiveness as determined by ITT analysis was 85.6% at 6 months and 66.1% at 12 months. Seven patients (5.9%) withdrew from the 2-DR and there was no virological failure.In real life, switching from a triple regimen with TAF to DTG-3TC or DTG-RPV dual therapy improves the lipid profile and is an effective and well-tolerated strategy.
- Published
- 2022
6. Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study
- Author
-
Hans-Jürgen Stellbrink, Feifan Zhang, Maria Del Mar Masiá, Yazdan Yazdanpanah, Cynthia McCoig, Kati Vandermeulen, Maria Luisa Montes-ramírez, Marty St. Clair, Christopher J Bettacchi, Gary Richmond, Hans Jaeger, David A. Margolis, Kenneth Sutton, Kimberly Y. Smith, Keikawus Arastéh, Rodica Van Solingen-Ristea, Marie-Aude Khuong-Josses, Daniel Podzamczer, Graham H.R. Smith, W Keith Henry, and William Spreen
- Subjects
medicine.medical_specialty ,business.industry ,Surrogate endpoint ,cabotegravir ,Lamivudine ,integrase strand transfer inhibitor ,long-acting ,nonnucleoside reverse transcriptase inhibitor ,Major Articles ,rilpivirine ,chemistry.chemical_compound ,Regimen ,AcademicSubjects/MED00290 ,Infectious Diseases ,Cabotegravir ,Oncology ,chemistry ,Maintenance therapy ,Tolerability ,Abacavir ,Internal medicine ,Rilpivirine ,Medicine ,business ,medicine.drug - Abstract
Background In the Long-Acting Antiretroviral Treatment Enabling Trial 2 (LATTE-2) phase 2b study, long-acting (LA) injectable cabotegravir + rilpivirine dosed every 8 weeks (Q8W) or every 4 weeks (Q4W) demonstrated comparable efficacy with daily oral antiretroviral therapy (ART) through 96 weeks in ART-naive adults with human immunodeficiency virus type 1 (HIV-1). Here we report efficacy, tolerability, and safety of cabotegravir + rilpivirine LA over approximately 5 years. Methods After 20 weeks of oral cabotegravir + abacavir/lamivudine, participants were randomized to cabotegravir + rilpivirine LA Q8W or Q4W or continue oral ART through the 96-week maintenance period. In the extension period through week 256, participants continued their current LA regimen (randomized Q8W/Q4W groups) or switched from oral ART to Q8W or Q4W LA therapy (extension-switch groups). Endpoints assessed included proportion of participants with HIV-1 RNA Results At week 256, 186 of 230 (81%) participants in randomized Q8W/Q4W groups and 41 of 44 (93%) participants in extension-switch groups had HIV-1 RNA 1 participant. Conclusions Cabotegravir + rilpivirine LA exhibited long-term efficacy and tolerability, demonstrating its durability as maintenance therapy for HIV-1 infection. Clinical Trials Registration. NCT02120352.
- Published
- 2021
7. Rat hepatitis E virus (Rocahepevirus ratti) in people living with HIV
- Author
-
María Casares-Jimenez, Antonio Rivero-Juarez, Pedro Lopez-Lopez, María Luisa Montes, Roser Navarro-Soler, Joaquín Peraire, Nuria Espinosa, María Remedios Alemán-Valls, Tránsito Garcia-Garcia, Javier Caballero-Gomez, Diana Corona-Mata, Ignacio Perez-Valero, Rainer G. Ulrich, and Antonio Rivero
- Subjects
Hepatitis E ,rat hepatitis E virus ,acute hepatitis ,HIV ,Zoonoses ,public health ,Infectious and parasitic diseases ,RC109-216 ,Microbiology ,QR1-502 - Abstract
ABSTRACTRat hepatitis E virus (ratHEV; species Rocahepevirus ratti) is considered a newly emerging cause of acute hepatitis of zoonotic origin. ratHEV infection of people living with HIV (PLWH) might portend a worse, as with hepatitis E virus (HEV; species Paslahepevirus balayani), and consequently this group may constitute a high-risk population. We aimed to evaluate the prevalence of ratHEV by measuring viral RNA and specific IgG antibodies in a large Spanish cohort of PLWH. Multicentre study conducted in Spain evaluating PLWHIV included in the Spanish AIDS Research Network (CoRIS). Patients were evaluated for ratHEV infection using PCR at baseline and anti-ratHEV IgG by dot blot analysis to evaluate exposure to ratHEV strains. Patients with detectable ratHEV RNA were followed-up to evaluate persistence of viremia and IgG seroconversion. Eight-hundred and forty-two individuals were tested. A total of 9 individuals showed specific IgG antibodies against ratHEV, supposing a prevalence of 1.1 (95% CI; 0.5%−2.1%). Of these, only one was reactive to HEV IgG antibodies by ELISA. One sample was positive for ratHEV RNA (prevalence of infection: 0.1%; 95% CI: 0.08%−0.7%). The case was a man who had sex with men exhibiting a slightly increased alanine transaminase level (49 IU/L) as only biochemical alteration. In the follow-up, the patients showed undetectable ratHEV RNA and seroconversion to specific ratHEV IgG antibodies. Our study shows that ratHEV is geographical broadly distributed in Spain, representing a potential zoonotic threat.
- Published
- 2024
- Full Text
- View/download PDF
8. Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir
- Author
-
Ramirez, Maria Luisa Montes, Vargas, Francisco X. Zamora, González-Garcia, Juan, Quereda, Carmen, Pérez-Elías, Maria Jesús, de Cea, Alvaro Mena, Barros, Carlos, Condés, Emilia, Moreno, Jose Sanz, Santos, Ignacio, Torralba, Miguel, Aldamiz-Echevarria, Teresa, and Moreno, Ana
- Published
- 2014
- Full Text
- View/download PDF
9. Global DNA methylation and telomere length as markers of accelerated aging in people living with HIV and non-alcoholic fatty liver disease
- Author
-
Elena Moreno, Javier Martínez-Sanz, Rosa Martín-Mateos, Jorge Díaz-Álvarez, Sergio Serrano-Villar, Diego Burgos-Santamaría, Laura Luna, María Jesús Vivancos, Ana Moreno-Zamora, María Jesús Pérez-Elías, Santiago Moreno, Fernando Dronda, María Luisa Montes, and Matilde Sánchez-Conde
- Subjects
DNA methylation ,MAFLD ,PLWH ,Biotechnology ,TP248.13-248.65 ,Genetics ,QH426-470 - Abstract
Abstract Metabolic-dysfunction-associated fatty liver disease (MAFLD) is a comorbidity that generally increases in people living with HIV (PLWH). This condition is usually accompanied by persistent inflammation and premature immune system aging. In this prospective cohort study, we describe a straightforward methodology for quantifying biomarkers of aging, such as DNA methylation and telomere length, in PLWH and in the context of another relevant condition, such as MAFLD. Fifty-seven samples in total, thirty-eight from PLWH and nineteen from non-PLWH participants with or without MAFLD, were obtained and subjected to DNA extraction from peripheral blood mononuclear cells (PBMCs). Global DNA methylation and telomere length quantification were performed using an adapted enzyme-linked immunosorbent assay (ELISA) and qPCR, respectively. The quantification results were analysed and corrected by clinically relevant variables in this context, such as age, sex, and metabolic syndrome. Our results show an increased association of these biomarkers in PLWH regardless of their MAFLD status. Thus, we propose including the quantification of these age-related factors in studies of comorbidities. This will allow a better understanding of the effect of comorbidities of HIV infection and MAFLD and prevent their effects in these populations in the future.
- Published
- 2023
- Full Text
- View/download PDF
10. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR
- Author
-
Ignacio De Los Santos Gil, José María Bellón Cano, Manuel Crespo, Juan González-García, Maria Luisa Montes, Belén Yélamos, María Ángeles Jiménez-Sousa, Francisco Arnalich Fernandez, Marta Montero, Chiara Fanciulli, José Ignacio Bernardino, Salvador Resino, Sonia Vázquez-Morón, Juan Berenguer, Víctor Hontañón Antoñana, Jose Luis Casado, Jose Arribas, Mª Jesus Perez Elias, Isidoro Martinez, Instituto de Salud Carlos III, Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF), Fundación para la Investigación y la Prevención del Sida en España, Ministerio de Sanidad, Servicios Sociales e Igualdad (España), UAM. Departamento de Medicina, [Vigón L, Vázquez-Morón S, Jiménez-Sousa MA] Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Madrid, Spain. [Berenguer J] Unidad de Enfermedades Infecciosas/VIH, Hospital General Universitario Gregorio Marañón, Madrid, Spain. Instituto de Investigación Sanitaria del Gregorio Marañón, Madrid, Spain. [González-García J] Unidad de VIH, Servicio de Medicina Interna, Hospital Universitario La Paz, Madrid, Spain. [Guardiola JM] Hospital Santa Creu i Sant Pau, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
0301 basic medicine ,Male ,Sustained Virologic Response ,Immune System Diseases::Immunologic Deficiency Syndromes::HIV Infections::HIV Seropositivity [DISEASES] ,HIV Infections ,Hepacivirus ,Neutralization ,law.invention ,0302 clinical medicine ,law ,Genotype ,Medicine ,Medicaments antivírics ,Phylogeny ,nucleótidos y nucleósidos de ácidos nucleicos::nucleósidos::ribonucleósidos::ribavirina [COMPUESTOS QUÍMICOS Y DROGAS] ,Multidisciplinary ,biology ,Hepatitis C virus ,virus diseases ,Middle Aged ,Viral Load ,Hepatitis C ,anti-HCV antibodies ,Titer ,Antirheumatic Agents ,Recombinant DNA ,Female ,aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::aminoácidos, péptidos y proteínas::proteínas::globulinas::globulinas séricas::inmunoglobulinas::anticuerpos::anticuerpos víricos::anticuerpos de las hepatitis::antciuerpos de la hepatitis C [COMPUESTOS QUÍMICOS Y DROGAS] ,Antibody ,Viral load ,Adult ,SVR ,Medicina ,Science ,Antiviral Agents ,Virus ,Article ,Antibodies ,03 medical and health sciences ,HIV/HCV-coinfected patients ,enfermedades del sistema inmune::síndromes de inmunodeficiencia::infecciones por VIH::seropositividad al VIH [ENFERMEDADES] ,Cell Line, Tumor ,Ribavirin ,Humans ,Nucleic Acids, Nucleotides, and Nucleosides::Nucleosides::Ribonucleosides::Ribavirin [CHEMICALS AND DRUGS] ,Retrospective Studies ,Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Serum Globulins::Immunoglobulins::Antibodies::Antibodies, Viral::Hepatitis Antibodies::Amino Acids, Peptides, and Proteins::Proteins::Hepatitis C Antibodies [CHEMICALS AND DRUGS] ,business.industry ,Anti hiv ,Interferon-alpha ,Hepatitis C Antibodies ,Virology ,Antibodies, Neutralizing ,digestive system diseases ,030104 developmental biology ,biology.protein ,Infeccions per VIH ,business ,030217 neurology & neurosurgery - Abstract
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who achieved sustained virological response (SVR) with pegIFNα+ribavirin anti-HCV therapy. Plasma samples at baseline and week 24 after SVR were used to perform neutralization assays against fve JFH1-based HCV recombinant viruses coding for E1 and E2 from genotypes 1a (H77), 1b (J4), 2a (JFH1), 3a (S52) and 4a (ED43). At baseline, the majority of plasma samples neutralized 1a, 1b, 2a, and 4a, but not 3a, genotypes. Twenty-four weeks following SVR, most neutralizing titers declined substantially. Furthermore, titers against 3a and 2a were not detected in many patients. Plasma samples with high HCV-nAb titers neutralized all genotypes, and the highest titers at the starting point correlated with the highest titers at week 24 after SVR. In conclusion, high titers of broad-spectrum HCV-nAbs were detected in HIV/HCV-coinfected individuals, however, those titers declined soon after SVR, This study was supported by grants from Instituto de Salud Carlos III (ISCIII; grant numbers PI14/01094 and PI17/00657 to JB, PI17/00903 to JGG, PI14CIII/00011 and PI17CIII/00003 to SR) and Ministerio de Sanidad, Servicios Sociales e Igualdad (grant number EC11-241). Te study was also funded by the RD16CIII/0002/0002, RD16/0025/0018, and RD16/0025/0017 projects as part of the Plan Nacional R+D+I and co-funded by ISCIII- Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER)
- Published
- 2019
11. Reasons for noncompliance with the national guidelines for initial antiretroviral therapy of HIV-infected patients in Spain, 2010-2015
- Author
-
Inés Suárez-García, Víctor Asensi Álvarez, INMA JARRIN, Esther Rodríguez-Gallego, Roberto Muga, DAVID DALMAU, Santos Del Campo, Maria Luisa Montes, José A. Oteo, Francisco Arnalich Fernandez, Vicente Boix, Félix Gutiérrez, Eulalia Valle-Garay, Marta Fernández-González, Juan Berenguer, and JOSE ALBERTO GARCIA GOMEZ
- Subjects
0301 basic medicine ,Pediatrics ,HIV Infections ,Comorbidity ,Practice guidelines ,law.invention ,Tratamiento médico ,0302 clinical medicine ,Randomized controlled trial ,law ,Pregnancy ,Antiretroviral Therapy, Highly Active ,Medicine ,Drug Interactions ,030212 general & internal medicine ,Practice Patterns, Physicians' ,Clinical Trials as Topic ,Guías de práctica clínica ,Middle Aged ,Cohort ,Practice Guidelines as Topic ,Cohort studies ,Female ,Guideline Adherence ,Risk assessment ,Cohort study ,Microbiology (medical) ,Adult ,medicine.medical_specialty ,Adolescent ,Anti-HIV Agents ,Sida ,030106 microbiology ,Estudios de cohortes ,Investigación médica ,Tratamiento antirretroviral ,Drug Costs ,Medication Adherence ,03 medical and health sciences ,Young Adult ,Pharmacotherapy ,Highly active antiretroviral therapy ,Antirretrovirales ,Physicians ,Humans ,Medical prescription ,Motivation ,business.industry ,Prescription Fees ,Clinical trial ,Regimen ,Spain ,business ,Follow-Up Studies - Abstract
[EN]: [Introduction]: Our aims were to investigate the adherence to national guidelines of initial antiretroviral therapy (ART) in the Spanish multicenter CoRIS cohort during the years 2010–2015, to identify the reasons for the prescription of nonrecommended treatments, and to explore the role of institutional constraints to guideline compliance. [Methods]: ART regimens were classified as recommended, alternative or nonrecommended according to the guidelines. Physicians were asked the reasons for prescribing nonrecommended regimens. Factors associated with the prescription of non recommended regimens were assessed using multivariable logistic regression. [Results]: During the study period, 586 (10.7%) of 5479 patients who started ART were given a regimen not recommended in the guidelines. The most frequent reasons for prescribing nonrecommended regimens were: enrolment in clinical trials (43.3%), comorbidities and/or interactions (10.2%), pregnancy (8.7%), and cost (7.7%). Among 37 participating centers, 16 (43%), treating 3561 patients, reported limitations related with the cost of ART, and 20 (54%), treating 1365 patients, reported restrictions for prescribing at least one recommended antiretroviral. In multivariable analysis, a higher risk of receiving nonrecommended regimens was associated with male gender, HIV acquisition by heterosexual transmission, low viral loads, initiation of treatment during the years 2011 to 2015, and initiation of treatment in a center with restricted access to at least one antiretroviral drug. [Conclusions]: Compliance to clinical guidelines was high. A high proportion of centres reported cost limitations for ART or restricted access to at least one recommended antiretroviral drug, with a significant impact on the choice of initial regimens., [ES]: [Introducción]: Nuestros objetivos fueron investigar la adecuación del tratamiento antirretroviral (TAR) inicial a las guías nacionales en la cohorte multicéntrica española CoRIS durante los años 2010-2015, identificar las razones para la prescripción de pautas no recomendadas y estudiar la influencia de limitaciones institucionales en el cumplimiento de las guías. [Métodos]: Se clasificaron las pautas de TAR en recomendadas, alternativas o no recomendadas según las guías de GeSIDA/Plan Nacional sobre el sida. Se preguntaron las razones para haber prescrito pautas no recomendadas a los médicos prescriptores. Se evaluaron los factores asociados a la prescripción de pautas no recomendadas mediante regresión logística multivariable. [Resultados]: Durante el periodo de estudio 586 (10,7%) de 5.479 pacientes que iniciaron TAR recibieron una pauta no recomendada. Las razones más frecuentes para prescribir pautas no recomendadas fueron: participación en ensayo clínico (43,3%), comorbilidades y/o interacciones (10,2%), embarazo (8,7%) y coste (7,7%). Entre los 37 centros participantes 16 (43%), que incluían 3.561 pacientes, referían limitaciones en el coste del TAR y 20 (54%), que incluían 1.365 pacientes, referían restricciones para la prescripción de al menos un fármaco recomendado. En el análisis multivariable el riesgo de recibir una pauta no recomendada se asoció a ser varón, adquisición del VIH por vía heterosexual, carga viral baja, inicio del tratamiento durante los años 2011 a 2015 e inicio del tratamiento en un centro con acceso restringido al menos a un antirretroviral. [Conclusiones]: El cumplimiento de las guías de TAR fue elevado. Una alta proporción de centros refirieron limitaciones de coste para el TAR o acceso restringido al menos a uno de los fármacos antirretrovirales recomendados; esto último influyó en la elección de pautas no recomendadas.
- Published
- 2019
12. Simplification to dual therapy (atazanavir/ritonavir + lamivudine) versus standard triple therapy [atazanavir/ritonavir + two nucleos(t)ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
- Author
-
Julian Olalla, Federico Pulido, Víctor Asensi Álvarez, ANTONIO OCAMPO HERMIDA, Anna Bonjoch, Antonio Rivero Román, Jose Molto, Maria Luisa Montes, José A. Oteo, Vicente Boix, Jose Antonio Perez-Molina, José Manuel Ramos Rincón, Jesus Fortun, Sergio Padilla, Esperanza Merino de Lucas, Eugenia Negredo, Jesús Troya García, Juan Pasquau, José Ignacio Bernardino, Rafael Rubio García, Félix Gutiérrez, Jordi Navarro, Antonio Rivero, Jose Arribas, Mª Jesus Perez Elias, JOSE LUIS PRADA, and Joaquín Portilla
- Subjects
Adult ,Male ,0301 basic medicine ,Microbiology (medical) ,medicine.medical_specialty ,Anti-HIV Agents ,030106 microbiology ,Population ,Pharmacology ,Gastroenterology ,Maintenance Chemotherapy ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Maintenance therapy ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,education ,Aged ,Aged, 80 and over ,education.field_of_study ,business.industry ,Lamivudine ,Middle Aged ,Viral Load ,Atazanavir ,Discontinuation ,Treatment Outcome ,Infectious Diseases ,Female ,Ritonavir ,business ,human activities ,Viral load ,medicine.drug - Abstract
OBJECTIVES We evaluated whether maintenance therapy with atazanavir/ritonavir plus lamivudine (ATV/r + 3TC) was non-inferior to ATV/r plus two nucleosides (ATV/r + 2NUCs) at 96 weeks of follow-up. METHODS SALT is a multicentre, open-label, non-inferiority clinical trial in HIV-1-infected virologically suppressed patients. Hepatitis B virus surface antigen-negative subjects with no previous treatment failure/resistance mutations and HIV-1-RNA
- Published
- 2016
13. Relationship between plasma bilirubin level and oxidative stress markers in HIV-infected patients on atazanavir-vs. efavirenz-based antiretroviral therapy
- Author
-
Consuelo Viladés, Nuria Espinosa, VERONICA ALBA ELVIRA, Jose-Ramon Blanco, Miriam Estebanez, Sergio Veloso Esteban, INMA JARRIN, Andrés Navarro Ruiz, Enrique Bernal Morell, Paloma Gijon, Mar Masiá, Livia Giner, Francesc Vidal, DAVID DALMAU, Montserrat Vargas Laguna, JUAN JOSE SIRVENT, Jesús Miguel López Dupla, Vicente Estrada, Maria Luisa Montes, Vicente Boix, Sergio Padilla, Esperanza Merino de Lucas, Dulcenombre Gomez-Garre, Susana Monge, Luis Fernando Lopez.Cortes, Jesus Mingorance, Rafael Rubio García, Félix Gutiérrez, Juan Berenguer, Cristina Gonzalez, Víctor Hontañón Antoñana, Jose Luis Casado, Jose Arribas, Mª Jesus Perez Elias, and Joaquín Portilla
- Subjects
Adult ,Cyclopropanes ,Male ,medicine.medical_specialty ,Efavirenz ,Bilirubin ,Atazanavir Sulfate ,HIV Infections ,030204 cardiovascular system & hematology ,Gastroenterology ,Plasma ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Pharmacology (medical) ,Prospective Studies ,030212 general & internal medicine ,Prospective cohort study ,Peroxidase ,business.industry ,Health Policy ,Confidence interval ,Benzoxazines ,Atazanavir ,Lipoproteins, LDL ,Oxidative Stress ,Phospholipases A2 ,Regimen ,Infectious Diseases ,Anti-Retroviral Agents ,chemistry ,Alkynes ,Immunology ,Female ,Ritonavir ,business ,Biomarkers ,medicine.drug - Abstract
Objectives Chronic oxidative stress (OS) may play a role in cardiovascular disease in HIV-infected patients, and increased bilirubin levels may have a beneficial role in counteracting OS. Atazanavir (ATV) inhibits UDP-glucuronosyl-transferase 1A1 (UGT1A1), thus increasing unconjugated bilirubin levels. We aimed to compare changes in OS markers in patients on ATV/ritonavir (ATV/r)- vs. efavirenz (EFV)-based first-line antiretroviral therapy (ART). Methods A multicentre, prospective cohort study of HIV-infected patients who started first-line ART with either ATV/r or EFV was conducted. Lipoprotein-associated phospholipase A2 (Lp-PLA2), myeloperoxidase (MPO) and oxidized low-density lipoprotein (oxLDL) were measured for 145 patients in samples obtained at baseline and after at least 9 months of ART during which the initial regimen was maintained and the patient was virologically suppressed. The change in OS markers was modelled using multiple linear regressions adjusting for baseline values and confounders. Results After adjustment for baseline variables, patients on ATV/r had a significantly greater decrease in Lp-PLA2 [estimated difference -16.3; 95% confidence interval (CI) -31.4, -1.25; P = 0.03] and a significantly smaller increase in OxLDL (estimated difference -21.8; 95% CI -38.0, -5.6; P < 0.01) relative to those on EFV, whereas changes in MPO were not significantly different (estimated difference 1.2; 95% CI -14.3, 16.7; P = 0.88). Adjusted changes in bilirubin were significantly greater for the ATV/r group than for the EFV group (estimated difference 1.33 mg/dL; 95% CI 1.03, 1.52 mg/dL; P < 0.01). Changes in bilirubin and changes in OS markers were significantly correlated. Conclusions When compared with EFV, ATV/r-based therapy was associated with lower levels of oxidative stress biomarkers, which was in part attributable to increased bilirubin levels.
- Published
- 2016
14. A gut microbiome signature for HIV and metabolic dysfunction-associated steatotic liver disease
- Author
-
Javier Martínez-Sanz, Alba Talavera-Rodríguez, Jorge Díaz-Álvarez, Marta Rosas Cancio-Suárez, Juan Miguel Rodríguez, Claudio Alba, María Luisa Montes, Rosa Martín-Mateos, Diego Burgos-Santamaría, Santiago Moreno, Sergio Serrano-Villar, and Matilde Sánchez-Conde
- Subjects
HIV ,MASLD ,NAFLD ,gut microbiome ,microbiome ,Immunologic diseases. Allergy ,RC581-607 - Abstract
IntroductionMetabolic dysfunction-associated steatotic liver disease (MASLD), has emerged as an increasingly recognized problem among people living with HIV (PLWH). The gut-liver axis is considered to be strongly implicated in the pathogenesis of MASLD. We aimed to characterize the gut microbiota composition in PLWH and MASLD and compare it with that of two control groups: PLWH without MASLD and individuals with MASLD without HIV infection.MethodsWe collected clinical data and stool samples from participants. Bacterial 16S rRNA genes were amplified, sequenced, and clustered into operational taxonomic unit. Alpha diversity was studied by Shannon and Simpson indexes. To study how different the gut microbiota composition is between the different groups, beta diversity estimation was evaluated by principal coordinate analysis (PCoA) using Bray-Curtis dissimilarity. To further analyze differences in microbiome composition we performed a linear discriminant analysis (LDA) effect size (LEfSe).ResultsWe included 30 HIV+MASLD+, 30 HIV+MASLD- and 20 HIV-MASLD+ participants. Major butyrate producers, including Faecalibacterium, Ruminococcus, and Lachnospira dominated the microbiota in all three groups. Shannon’s and Simpson’s diversity metrics were higher among MASLD+ individuals (Kruskal-Wallis p = 0.047). Beta diversity analysis showed distinct clustering in MASLD-, with MASLD+ participants overlapping regardless of HIV status (ADONIS significance
- Published
- 2023
- Full Text
- View/download PDF
15. Dual treatment with lopinavir–ritonavir plus lamivudine versus triple treatment with lopinavir–ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): a randomised, open-label, non-inferiority trial
- Author
-
Federico Pulido, Esteban Ribera, ANTONIO OCAMPO HERMIDA, Ignacio Pérez Valero, Josep Mallolas Masferrer, Maria Milagro Montero, Vicente Estrada, Juan González-García, Maria Luisa Montes, Vicente Boix, Marta Montero, Pablo Ryan, Esperanza Merino de Lucas, Jesús Troya García, José Ignacio Bernardino, André Cabié, Maria De Lagarde, Sylvie ABEL, Rafael Rubio García, Jordi Navarro, Hernando Knobel, Jose Luis Casado, Jose Arribas, and Joaquín Portilla
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,Population ,Lopinavir/ritonavir ,HIV Infections ,Emtricitabine ,Deoxycytidine ,Gastroenterology ,Lopinavir ,Maintenance Chemotherapy ,Internal medicine ,medicine ,Humans ,education ,education.field_of_study ,Ritonavir ,Reverse-transcriptase inhibitor ,business.industry ,virus diseases ,Lamivudine ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Hepatitis B ,medicine.disease ,CD4 Lymphocyte Count ,Intention to Treat Analysis ,Surgery ,Infectious Diseases ,HIV-1 ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Summary Background Our objective was to assess therapeutic non-inferiority of dual treatment with lopinavir–ritonavir and lamivudine to triple treatment with lopinavir–ritonavir plus two nucleos(t)ides for maintenance of HIV-1 viral suppression. Methods In this randomised, open-label, non-inferiority trial, we recruited patients from 32 HIV units in hospitals in Spain and France. Eligible patients were HIV-infected adults (aged ≥18 years) with HIV-1 RNA of less than 50 copies per mL, for at least 6 months on triple treatment with lopinavir–ritonavir (twice daily) plus lamivudine or emtricitabine and a second nucleos(t)ide, with no resistance or virological failure to these drugs, and no positive hepatitis B serum surface antigen. Investigators at each centre randomly assigned patients (1:1; block size of four; stratified by time to suppression [ 1 year] and nadir CD4 cell count [ 100 cells per μL]; computer-generated random sequence) to continue triple treatment or switch to dual treatment (oral lopinavir 400 mg and oral ritonavir 100 mg twice daily plus oral lamivudine 300 mg once daily). The primary endpoint was response to treatment in the intention-to-treat population (all randomised patients) at 48 weeks. The non-inferiority margin was 12%. This study is registered with ClinicalTrials.gov, number NCT01471821. Findings Between Oct 1, 2011, and April 1, 2013, we randomly assigned 250 participants to continue triple treatment (127 [51%] patients) or switch to dual treatment (123 [49%] patients). In the intention-to-treat population, 110 (86·6%) of 127 patients in the triple-treatment group responded to treatment versus 108 (87·8%) of 123 in the dual-treatment group (difference −1·2% [95% CI −9·6 to 7·3]; p=0·92), meeting the criteria for non-inferiority. Serious adverse events occurred in eight (7%) patients in the triple-treatment group and five (4%) in the dual-treatment group (p=0·515), and study drug discontinuations due to adverse events occurred in four (3%) in the triple-treatment group and one (1%) in the dual-treatment group (p=0·223). Interpretation Dual treatment with lopinavir–ritonavir plus lamivudine has non-inferior therapeutic efficacy and is similarly tolerated to triple treatment. Funding AbbVie and Red Tematica Cooperativa de Investigacion en Sida.
- Published
- 2015
16. Dual treatment with atazanavir–ritonavir plus lamivudine versus triple treatment with atazanavir–ritonavir plus two nucleos(t)ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomised, open-label, non-inferiority trial
- Author
-
Julian Olalla, Federico Pulido, Miriam Estebanez, Víctor Asensi Álvarez, ANTONIO OCAMPO HERMIDA, Ignacio Pérez Valero, Anna Bonjoch, Antonio Rivero Román, Maria Luisa Montes, José A. Oteo, Vicente Boix, Jose Antonio Perez-Molina, José Manuel Ramos Rincón, Jesus Fortun, Sergio Padilla, Esperanza Merino de Lucas, Eugenia Negredo, Jesús Troya García, Juan Pasquau, José Ignacio Bernardino, Maria De Lagarde, Javier De La Torre-Lima, Rafael Rubio García, Félix Gutiérrez, Jordi Navarro, Juan Berenguer, Antonio Rivero, Otilia Bisbal, Jose Arribas, Mª Jesus Perez Elias, JOSE LUIS PRADA, and Joaquín Portilla
- Subjects
Adult ,Male ,medicine.medical_specialty ,Anti-HIV Agents ,Pyridines ,Atazanavir Sulfate ,Population ,Organophosphonates ,HIV Infections ,Emtricitabine ,Deoxycytidine ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,medicine ,Clinical endpoint ,Humans ,Tenofovir ,education ,education.field_of_study ,Ritonavir ,Drug Substitution ,business.industry ,Adenine ,Lamivudine ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Atazanavir ,Surgery ,Infectious Diseases ,HIV-1 ,RNA, Viral ,Reverse Transcriptase Inhibitors ,Drug Therapy, Combination ,Female ,business ,Oligopeptides ,Zidovudine ,Viral load ,medicine.drug - Abstract
Summary Background Problems associated with lifelong antiretroviral therapy, such as need for strict adherence, drug-related toxic effects, difficulties with treatment schedules, and cost, mean that simplification strategies should be sought. We aimed to explore the efficacy and safety of dual treatment with atazanavir–ritonavir plus lamivudine as an option to switch to from standard combination antiretroviral therapy in patients with an HIV-1 infection who are virologically suppressed. Methods In this randomised, open-label, non-inferiority trial, we recruited patients aged 18 years and older with chronic HIV-1 infection and no previous treatment failure or resistance, and with HIV-1 RNA of less than 50 copies per mL for at least 6 months, negative hepatitis B virus surface antigen, and good general health, from 30 hospitals in Spain. Exclusion criteria were switch in antiretroviral therapy during the previous 4 months, previous virological failure, pregnancy or breastfeeding, Gilbert's syndrome, use of contraindicated drugs, grade 4 laboratory abnormalities, and previous intolerance to any of the study drugs. We randomly assigned patients (1:1; stratified by active hepatitis C virus infection and previous treatment; computer-generated random number sequence) to dual treatment with oral atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus lamivudine (300 mg once daily) or triple treatment with oral atazanavir (300 mg once daily) and ritonavir (100 mg once daily) plus two nucleos(t)ide reverse transcriptase inhibitors at the discretion of the investigators. The primary endpoint was virological response, defined as HIV-1 RNA of less than 50 copies per mL at week 48, in the per-protocol population, with a non-inferiority margin of 12%. We included patients who received at least one dose of the study drug in the safety analysis. This study is registered at ClinicalTrials.gov, number NCT01307488. Findings Between Sept 29, 2011, and May 2, 2013, we randomly assigned 286 patients (143 [50%] to each group). At week 48 in the per-protocol population, 112 (84%) of 133 patients had virological response in the dual-treatment group versus 105 (78%) of 135 in the triple-treatment group (difference 6% [95% CI −5 to 16%), showing non-inferiority at the prespecified level. 14 (5%) patients developed severe adverse events (dual treatment six [4%]; triple treatment eight [6%]), none of which we deemed related to the study drug. Grade 3–4 adverse events were similar between groups (dual treatment 77 [55%] of 140; triple treatment 78 [55%] of 141). Treatment discontinuations were less frequent in the dual-treatment group (three [2%]) than in the triple-treatment group (ten [7%]; p=0·047). Interpretation In our trial, dual treatment was effective, safe, and non-inferior to triple treatment in patients with an HIV-1 infection who are virologically suppressed who switch antiretroviral therapy because of toxic effects, intolerance, or simplification. This combination has the potential to suppress some of the long-term toxic effects associated with nucleos(t)ide reverse transcriptase inhibitors, preserve future treatment options, and reduce the cost of antiretroviral therapy. Funding Bristol Myers-Squibb and Fundacion SEIMC-GESIDA.
- Published
- 2015
17. Persistently altered liver test results in hepatitis C patients after sustained virological response with direct-acting antivirals
- Author
-
Lourdes Domínguez-Domínguez, Federico Pulido, Valentín Cuervas-Mons, LUZ MARTÍN CARBONERO, Eulalia Valencia, Juan González-García, Maria Luisa Montes, Pablo Ryan, Jesús Troya García, José Ignacio Bernardino, and Rafael Rubio García
- Subjects
Adult ,Male ,medicine.medical_specialty ,Cirrhosis ,Adolescent ,Sustained Virologic Response ,Biopsy ,Gastroenterology ,Antiviral Agents ,03 medical and health sciences ,Liver disease ,Young Adult ,0302 clinical medicine ,Liver Function Tests ,Virology ,Internal medicine ,Nonalcoholic fatty liver disease ,medicine ,Prevalence ,Humans ,Aspartate Aminotransferases ,Prospective Studies ,Aged ,Aged, 80 and over ,Hepatology ,medicine.diagnostic_test ,business.industry ,Fatty liver ,Alanine Transaminase ,Hepatitis C ,gamma-Glutamyltransferase ,Hepatitis C, Chronic ,Middle Aged ,medicine.disease ,Infectious Diseases ,030220 oncology & carcinogenesis ,Liver biopsy ,Elasticity Imaging Techniques ,030211 gastroenterology & hepatology ,Female ,Liver function tests ,business ,Transient elastography - Abstract
Guidelines recommend evaluating persistent alteration of liver tests in HCV-infected patients after sustained virological response (SVR) and its influence on liver disease progression. We studied the prevalence, etiology, associated factors and evolutionary implications of persistent alteration of liver tests in HCV patients after direct-acting antivirals (DAA)-induced SVR. This was a prospective study of HCV-infected patients and SVR after DAA. Those with another previously diagnosed liver disease were excluded. Persistent alteration of liver tests was defined as any increase in ALT, AST or GGT at SVR12 and SVR24. Causes were determined according to standard clinical practice, including liver biopsy and follow-up transient elastography. A total of 1112 patients were included (70.8% males, median age 53 years, 38.8% cirrhosis, 34.9% interferon-experienced, 56.8% HIV-coinfected). Persistent alteration of liver tests was detected in 130/1112 patients (11.7% [95%CI: 9.7-13.6]). Its frequency differed between HCV-monoinfected (45/480: 9.4% [95%CI: 6.7-12.1]) and HIV-coinfected (85/632: 13.5% [95%CI: 10.7-16.2]) (P = .046). In multivariable analysis, cirrhosis (OR 2.12; 95%CI: 1.28-3.53; P = .004) and baseline transient elastography values (OR 1.03; 95%CI: 1.01-1.04; P = .000) were associated with persistent alteration of liver tests. The main etiologies were clinical diagnosis suggestive of nonalcoholic fatty liver disease in 47 (36.2%), alcohol in 30 (23.1%) and drug consumption in 19 (14.6%). Baseline and follow-up transient elastography was performed in 594 patients and showed a significantly different decrease in patients who did or did not have a persistent alteration of liver tests (-21.1% vs -30%, respectively; P = .003), independently of sex, HIV status or baseline TE value. In conclusion, persistent alteration of liver tests is not infrequent after SVR. It is associated with cirrhosis and baseline transient elastography, and the main cause is fatty liver. According to transient elastography changes, persistent alteration of liver tests seems to affect the course of liver disease.
- Published
- 2017
18. Effects of frailty, geriatric syndromes, and comorbidity on mortality and quality of life in older adults with HIV
- Author
-
Fátima Brañas, Miguel Torralba, Antonio Antela, Jorge Vergas, Margarita Ramírez, Pablo Ryan, Fernando Dronda, María José Galindo, Isabel Machuca, María Jesús Bustinduy, Alfonso Cabello, María Luisa Montes, Matilde Sánchez-Conde, and FUNCFRAIL study group
- Subjects
HIV ,Frailty ,Geriatric syndromes ,Mortality ,Quality of life ,Geriatrics ,RC952-954.6 - Abstract
Abstract Background To understand the effects of frailty, geriatric syndromes, and comorbidity on quality of life and mortality in older adults with HIV (OAWH). Methods Cross-sectional study of the FUNCFRAIL multicenter cohort. The setting was outpatient HIV-Clinic. OAWH, 50 year or over were included. We recorded sociodemographic data, HIV infection-related data, comorbidity, frailty, geriatric syndromes (depression, cognitive impairment, falls and malnutrition), quality of life (QOL) and the estimated risk of all-cause 5-year mortality by VACS Index. Association of frailty with geriatric syndromes and comorbidity was evaluated using the Cochran-Mantel-Haenszel test. Results Seven hundred ninety six patients were included. 24.7% were women, mean age was 58.2 (6.3). 14.7% were 65 or over. 517 (65%) patients had ≥3 comorbidities, ≥ 1 geriatric syndrome and/or frailty. There were significant differences in the estimated risk of mortality [(frailty 10.8%) vs. (≥ 3 comorbidities 8.2%) vs. (≥ 1 geriatric syndrome 8.2%) vs. (nothing 6.2%); p = 0.01] and in the prevalence of fair or poor QOL [(frailty 71.7%) vs. (≥ 3 comorbidities 52%) vs. (≥ 1 geriatric syndrome 58.4%) vs. (nothing 51%); p = 0.01]. Cognitive impairment was significantly associated to mortality (8.7% vs. 6.2%; p = 0.02) and depression to poor QOL [76.5% vs. 50%; p = 0.01]. Conclusions Frailty, geriatric syndromes, and comorbidity had negative effects on mortality and QOL, but frailty had the greatest negative effect out of the three factors. Our results should be a wake-up call to standardize the screening for frailty and geriatric syndromes in OAWH in the clinical practice. Trial registration NCT03558438.
- Published
- 2023
- Full Text
- View/download PDF
19. Etravirine-based antiretroviral therapy in HIV/hepatitis C virus coinfected advanced fibrosis patients receiving triple therapy against hepatitis C virus with telaprevir
- Author
-
Alvaro Mena de Cea, María J Pérez-Elías, Miguel Torralba, Francisco X. Zamora Vargas, José Sanz Moreno, Teresa Aldámiz-Echevarría, Maria Luisa Montes Ramirez, Emilia Condes, Juan González-García, Carlos Barros, Ignacio Santos, Ana Moreno, and Carmen Quereda
- Subjects
Adult ,Liver Cirrhosis ,Male ,Drug-Related Side Effects and Adverse Reactions ,Hepatitis C virus ,Immunology ,Human immunodeficiency virus (HIV) ,Etravirine ,HIV Infections ,medicine.disease_cause ,Antiviral Agents ,Hepatitis ,Telaprevir ,Cohort Studies ,Tratamiento médico ,Nitriles ,medicine ,Humans ,Immunology and Allergy ,Retrospective Studies ,Coinfection ,SIDA ,business.industry ,Hepatitis C, Chronic ,Middle Aged ,Fibrosis ,Antiretroviral therapy ,Virology ,Advanced fibrosis ,Pyridazines ,Pyrimidines ,Treatment Outcome ,Infectious Diseases ,Spain ,Female ,business ,Oligopeptides ,medicine.drug - Abstract
Sin financiación 5.554 JCR (2014) Q1, 5/33 Virology, 21/148 Immunology, 7/78 Infectious Diseases UEM
- Published
- 2014
20. Infecciones cutáneas y de partes blandas por micobacterias no tuberculosas
- Author
-
Maria Luisa Montes, Jaime Esteban Moreno, and Fernando Alcaide
- Subjects
Microbiology (medical) ,Mycobacterium kansasii ,medicine.medical_specialty ,biology ,business.industry ,Mycobacterium chelonae ,Mycobacterium abscessus ,bacterial infections and mycoses ,biology.organism_classification ,Microbiology ,Surgery ,Mycobacterium ulcerans ,medicine ,Nontuberculous mycobacteria ,Mycobacterium fortuitum ,Mycobacterium xenopi ,business ,Mycobacterium marinum - Abstract
The frequency of isolation as well as the number of species of non-tuberculous mycobacteria (NTM) has increased in the last years. Nearly every pathogenic species of NTM may cause skin and soft tissue infections, but rapidly growing mycobacteria (Mycobacterium fortuitum, Mycobacterium chelonae and Mycobacterium abscessus), Mycobacterium marinum and Mycobacterium ulcerans are the most commonly involved. Many of these cutaneous mycobacteriosis, such as rapidly growing mycobacteria, M. marinum, Mycobacterium avium complex, Mycobacterium kansasii or Mycobacterium xenopi are world-wide distributed. In contrast, some others have a specific geographical distribution. This is the case of M. ulcerans, which causes a cutaneous diseases endemic of Central and West Africa (Buruli ulcer) and Australia (Bairnsdale ulcer), being the third mycobacterial infection after tuberculosis and leprosy. Cutaneous mycobacteriosis usually appear either after contact of traumatic or surgical wounds with water or other contaminated products, or, secondarily, as a consequence of a disseminated mycobacterial disease, especially among immunosuppressed patients. For an early diagnosis, it is necessary to maintain a high degree of suspicion in patients with chronic cutaneous diseases and a history of trauma, risk exposure and negative results of conventional microbiological studies. In general, individualized susceptibility testing is not recommended for most NTM infections, except for some species, and in case of therapeutic failure. Treatment includes a combination of different antimicrobial agents, but it must be taken into account that NTM are resistant to conventional antituberculous drugs. Severe cases or those with deep tissues involvement could also be tributary of surgical resection.
- Published
- 2010
21. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus
- Author
-
ANTONIO HERNANDO GRANDE, Federico Pulido, Ignacio De Los Santos Gil, José María Bellón Cano, Josep Mallolas Masferrer, Juan González-García, Maria Luisa Montes, Matilde Sanchez-Conde, Montserrat Laguno Centeno, Rafael Rubio García, Juan Berenguer, Asuncion Hernando, and Jose Arribas
- Subjects
Adult ,Male ,medicine.medical_specialty ,medicine.medical_treatment ,Hepatitis C virus ,HIV Infections ,Liver transplantation ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,Cohort Studies ,chemistry.chemical_compound ,Liver disease ,Internal medicine ,Ribavirin ,medicine ,Humans ,Hepatology ,business.industry ,virus diseases ,Hepatitis C ,Hepatitis C, Chronic ,medicine.disease ,digestive system diseases ,Treatment Outcome ,chemistry ,Immunology ,Drug Therapy, Combination ,Female ,Interferons ,business ,Viral hepatitis ,Viral load - Abstract
Human immunodeficiency virus (HIV) infection modifies the natural history of chronic hepatitis C, thus promoting more rapid progression to cirrhosis and end-stage liver disease. The objective of our study was to determine whether hepatitis C virus (HCV) clearance is associated with improved clinical outcomes in patients positive for HIV and HCV. It was an ambispective cohort study carried out in 11 HIV units in Spain and involved 711 consecutive patients positive for HIV/HCV who started interferon plus ribavirin therapy between 2000 and 2005. We measured sustained virologic response (SVR), i.e., undetectable HCV RNA at 24 weeks after the end of treatment, and clinical outcomes, defined as death (liver-related or non–liver-related), liver decompensation, hepatocellular carcinoma, and liver transplantation. Of 711 patients who were positive for HIV/HCV, 31% had SVR. During a mean follow-up of 20.8 months (interquartile range: 12.2-38.7), the incidence rates per 100 person-years of overall mortality, liver-related mortality, and liver decompensation were 0.46, 0.23, and 0.23 among patients with SVR and 3.12, 1.65, and 4.33 among those without SVR (P = 0.003, 0.028, and
- Published
- 2009
22. Didanosine, Lamivudine, and Efavirenz versus Zidovudine, Lamivudine, and Efavirenz for the Initial Treatment of HIV Type 1 Infection: Final Analysis (48 Weeks) of a Prospective, Randomized, Noninferiority Clinical Trial, GESIDA 3903
- Author
-
Víctor Asensi Álvarez, Esteban Ribera, Ignacio De Los Santos Gil, Manuel Marquez, Paloma Gijon, ANTONIO OCAMPO HERMIDA, Juan M. García-Lechuz, Maria Luisa Montes, Vicenç Falcó, MARIA PEÑARANDA VERA, Carlos Alonso-Villaverde, Jose Antonio Perez-Molina, Juan Pablo Horcajada, Marta Montero, Francisco Jover, Juan Pasquau, Matilde Sanchez-Conde, Galo Peralta, Alfonso Del Arco Jiménez, Javier De La Torre-Lima, Juan Berenguer, Jose Arribas, Luis Enrique Morano Amado, Mª Jesus Perez Elias, Inma Ocana, and JOSE LUIS PRADA
- Subjects
Adult ,Cyclopropanes ,Male ,Microbiology (medical) ,medicine.medical_specialty ,Efavirenz ,Anti-HIV Agents ,HIV Infections ,Severity of Illness Index ,Zidovudine ,chemistry.chemical_compound ,Antiretroviral Therapy, Highly Active ,Internal medicine ,medicine ,Humans ,Prospective Studies ,Didanosine ,Intention-to-treat analysis ,Reverse-transcriptase inhibitor ,business.industry ,virus diseases ,Lamivudine ,Lamivudine/Zidovudine ,Middle Aged ,Viral Load ,Virology ,Benzoxazines ,CD4 Lymphocyte Count ,Treatment Outcome ,Infectious Diseases ,Tolerability ,chemistry ,Alkynes ,HIV-1 ,RNA, Viral ,Female ,business ,medicine.drug - Abstract
BACKGROUND The combination of didanosine, lamivudine, and efavirenz (ddI/3TC/EFV) for the initial treatment of human immunodeficiency virus type 1 (HIV-1) infection has been insufficiently analyzed in clinical trials. METHODS We conducted an open-label, randomized study to compare the noninferiority of ddI/3TC/EFV with the lamivudine-zidovudine tablet and EFV (COM/EFV), both administered with food to improve tolerability and convenience. Patients were stratified by HIV-1 RNA level of or =5.0 log(10) copies/mL. The primary end point was the percentage of patients with an HIV-1 RNA level of
- Published
- 2008
23. Association of baseline CD4+ cell count and HIV-RNA on sustained virologic response to interferon-ribavirin in HIV/HCV coinfected patients
- Author
-
Aldamiz-Echevarria, Teresa, Gonzalez-Garcia, Juan, Wichmann, Miguel A., Crespo, Manel, Lopez-Aldeguer, Jose, Quereda, Carmen, Tellez, Maria J., Galindo, Maria J., Sanz, Jose, Santos, Ignacio, Guardiola, Josep M., Bellon, Jose M., Maria Luisa Montes, Berenguer, Juan, and Gesida Hiv-Hcv Cohort Study Grp
- Subjects
Male ,Sustained viral response ,Time Factors ,Hepacivirus ,Specialties of internal medicine ,HIV Infections ,Chronic hepatitis C ,Gastroenterology ,Interferó pegilat ,chemistry.chemical_compound ,Pegylated interferon ,Risk Factors ,Odds Ratio ,Resposta viral sostinguda ,biology ,Coinfection ,Human immunodeficiency virus ,virus diseases ,General Medicine ,Hepatitis C ,Viral Load ,Virus de la inmunodeficiencia humana ,Treatment Outcome ,RC581-951 ,RNA, Viral ,Female ,Viral load ,medicine.drug ,Hepatitis C crónica ,Cart ,Adult ,medicine.medical_specialty ,Genotype ,616.9 ,Anti-HIV Agents ,Antiviral Agents ,Hepatitis C crònica ,Respuesta viral sostenida ,Interferón pegilado ,Predictive Value of Tests ,Internal medicine ,Ribavirin ,medicine ,Humans ,Virus de la immunodeficiència humana ,Retrospective Studies ,Hepatology ,business.industry ,HIV ,Odds ratio ,medicine.disease ,biology.organism_classification ,Confidence interval ,digestive system diseases ,CD4 Lymphocyte Count ,Logistic Models ,chemistry ,Spain ,Immunology ,Multivariate Analysis ,Interferons ,business ,Pegilat interfered - Abstract
Background and rationale for the study. We assessed the association of CD4+ T-cell counts and HIV-RNA onsustained viral response (SVR) after therapy with pegylated interferon and ribavirin (PR) in HIV/HCV coin-fected patients. We examined two large cohorts of coinfected patients treated with PR in Spain between2000 and 2008. SVR was defined as undetectable HCV-RNA at 24 weeks after the end of PR. Results.Westudied 1682 patients, of whom 38% achieved SVR. Baseline factors independently associated with reducedodds of SVR included genotype 1 or 4, HCV-RNA > 500,000 IU/mL, advanced liver fibrosis, CDC clinical cate-gory C, and detectable HIV-RNA. By multivariate logistic regression analysis, we found that, in comparisonwith patients with combination antiretroviral therapy (cART) and undetectable HIV-RNA, the odds ratio[95% confidence interval (CI)] of SVR was 0.56 (0.41-0.78) for cART and detectable HIV-RNA, 0.86 (0.56-2.57)for no-cART and detectable HIV-RNA, and 1.38 (0.74-2.57) for no-cART and undetectable HIV-RNA. Conclu-sions.Detectable HIV-RNA, but not CD4+ T-cell count, was associated with reduced odds of SVR. However,this finding was only confirmed for cART and detectable HIV-RNA, raising the question as whether this rep-resents a true association of HIV-RNA on response to PR or a spurious association due to poor adherenceto treatment. info:eu-repo/semantics/publishedVersion
- Published
- 2015
24. Severity of cardiovascular disease outcomes among patients with HIV is related to markers of inflammation and coagulation
- Author
-
Emilio Bouza, Federico Pulido, Esper Kallas, Janak Koirala, Brygida Knysz, LUZ MARTÍN CARBONERO, Ignacio Pérez Valero, Pablo Okhuysen, DAVID DALMAU, Clifford Leen, Vicente Estrada, Juan González-García, Maria Luisa Montes, Moreno-Cuerda Victor, Matti Ristola, Lorenzo Magenta, Lars Østergaard, Aleksandra Szymczak, Sean Emery, Angèle Gayet-Ageron, Michael Kozal, André Cabié, Małgorzata Inglot, Nicholas Andrew Medland, Philippa Easterbrook, Jose Arribas, ANDREA COSTANTINI, Alvaro Humberto Borges, Robert Colebunders, Dermatology, Global Health, Graduate School, AII - Amsterdam institute for Infection and Immunity, APH - Amsterdam Public Health, and Universitat de Barcelona
- Subjects
Male ,Epidemiology ,HIV Infections ,Disease ,cardiovascular disease ,inflammation ,Adult ,Biological Markers ,C-Reactive Protein ,Cardiovascular Diseases ,Female ,Fibrin Fibrinogen Degradation Products ,Humans ,Inflammation ,Interleukin-6 ,Middle Aged ,Odds Ratio ,Blood Coagulation ,Medicine ,Original Research ,education.field_of_study ,biology ,Biochemical markers ,Hazard ratio ,Blood coagulation ,Inflamació ,3. Good health ,Cardiovascular diseases ,Marcadors bioquímics ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,HIV infections ,medicine.medical_specialty ,Population ,Internal medicine ,cardiovascular diseases ,education ,Interleukin 6 ,Coagulació sanguínia ,Malalties cardiovasculars ,business.industry ,C-reactive protein ,Odds ratio ,Confidence interval ,Surgery ,biology.protein ,Infeccions per VIH ,business ,Biomarkers - Abstract
Background In the general population, raised levels of inflammatory markers are stronger predictors of fatal than nonfatal cardiovascular disease ( CVD ) events. People with HIV have elevated levels of interleukin‐6 ( IL ‐6), high‐sensitivity C‐reactive protein (hs CRP ), and D‐dimer; HIV ‐induced activation of inflammatory and coagulation pathways may be responsible for their greater risk of CVD . Whether the enhanced inflammation and coagulation associated with HIV is associated with more fatal CVD events has not been investigated. Methods and Results Biomarkers were measured at baseline for 9764 patients with HIV and no history of CVD . Of these patients, we focus on the 288 that experienced either a fatal (n=74) or nonfatal (n=214) CVD event over a median of 5 years. Odds ratios ( OR s) (fatal versus nonfatal CVD ) (95% confidence intervals [ CIs ]) associated with a doubling of IL ‐6, D‐dimer, hs CRP , and a 1‐unit increase in an IL ‐6 and D‐dimer score, measured a median of 2.6 years before the event, were 1.39 (1.07 to 1.79), 1.40 (1.10 to 1.78), 1.09 (0.93 to 1.28), and 1.51 (1.15 to 1.97), respectively. Of the 214 patients with nonfatal CVD , 23 died during follow‐up. Hazard ratios (95% CI ) for all‐cause mortality were 1.72 (1.28 to 2.31), 1.73 (1.27 to 2.36), 1.44 (1.15 to 1.80), and 1.88 (1.39 to 2.55), respectively, for IL ‐6, D‐dimer, hs CRP , and the IL ‐6 and D‐dimer score. Conclusions Higher IL ‐6 and D‐dimer levels reflecting enhanced inflammation and coagulation associated with HIV are associated with a greater risk of fatal CVD and a greater risk of death after a nonfatal CVD event. Clinical Trial Registration URL: http://www.clinicaltrial.gov Unique identifier: SMART: NCT00027352, ESPRIT: NCT00004978, SILCAAT: NCT00013611.
- Published
- 2014
25. Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: the SPIRAL study
- Author
-
Consuelo Viladés, Ferran Torres, Esteban Ribera, Adrian Curran, Vicente Estrada, Maria Luisa Montes, Vicente Boix, Matilde Sanchez-Conde, Javier Murillas Angoiti, Félix Gutiérrez, Juan Berenguer, Hernando Knobel, Jose Arribas, and Joaquín Portilla
- Subjects
Adult ,Male ,medicine.medical_treatment ,Immunology ,Integrase inhibitor ,HIV Infections ,Biology ,Pharmacology ,Raltegravir Potassium ,Antiretroviral Therapy, Highly Active ,medicine ,Immunology and Allergy ,Humans ,Protease inhibitor (pharmacology) ,HIV Integrase Inhibitors ,Adverse effect ,Protease ,Ritonavir ,virus diseases ,HIV Protease Inhibitors ,Middle Aged ,Viral Load ,Raltegravir ,Lipids ,Pyrrolidinones ,CD4 Lymphocyte Count ,Infectious Diseases ,Treatment Outcome ,Enzyme inhibitor ,biology.protein ,HIV-1 ,RNA, Viral ,Female ,medicine.drug - Abstract
Background Switching to raltegravir in selected patients treated with ritonavir-boosted protease inhibitors may result in similar efficacy and lower plasma lipids. Methods SPIRAL is a 48-week multicentre, open-label trial in which HIV-infected adults with less than 50 copies/ml of plasma HIV RNA for at least the previous 6 months on ritonavir-boosted protease inhibitor-based therapy were randomized (1: 1) to switch from the ritonavir-boosted protease inhibitor to raltegravir or to continue on ritonavir-boosted protease inhibitor-based therapy. Primary endpoint was the proportion of patients free of treatment failure (noncompleter = failure) at 48 weeks. SPIRAL study was powered to show noninferior efficacy of raltegravir-based therapy with a margin of -12.5%. Results Two hundred and seventy-three patients assigned to switch to raltegravir (n = 139) or to continue ritonavir-boosted protease inhibitor (n = 134) were included in the efficacy analysis. At 48 weeks, 89.2% (raltegravir-based therapy) and 86.6% (ritonavir-boosted protease inhibitor-based therapy) of the patients remained free of treatment failure [difference 2.6%; 95% confidence interval (CI) -5.2 to 10.6]. A total of 96.9% (raltegravir-based therapy) and 95.1% (ritonavir-boosted protease inhibitor-based therapy) of the patients remained free of virological failure (difference 1.8%; 95% CI -3.5 to 7.5). Switching to raltegravir was associated with significant decreases in plasma lipids and total-to-HDL cholesterol ratio relative to continuing ritonavir-boosted protease inhibitor. Severe adverse events and study drug discontinuations due to any adverse event occurred in 4 and 2% of the patients in each group. Conclusion In patients with sustained virological suppression on ritonavir-boosted protease inhibitor-based therapy, switching from ritonavir-boosted protease inhibitor to raltegravir demonstrated noninferior efficacy and resulted in a better lipid profile at 48 weeks than continuing ritonavir-boosted protease inhibitor.
- Published
- 2010
26. [Demyelinating disease in human immunodeficiency virus-infected patients without severe immunodepression]
- Author
-
Miriam, Estébanez-Muñoz, Maria Luisa, Montes, Pilar, Ruiz-Seco, Aranzazu, Royo-Orejas, Juan, González-García, and José Ramón, Arribas
- Subjects
Adult ,Male ,Cross-Sectional Studies ,Humans ,Female ,HIV Infections ,Demyelinating Diseases ,Retrospective Studies - Abstract
Human immunodeficiency virus (HIV) infected patients who did not have severe immunodepression were analysed for multiple demyelinating lesions.Patients with a CD4 greater than 200/μL were selected after a search was made in a computerised data base.Four patients were found, three were co-infected with hepatitis C virus (HCV), with one of them on treatment with peg-interferón α-2b and ribavirin.HIV infected patients can develop demyelinating disease without having severe immunodepression, probably favoured by other factors, such as co-infection wIth HCV.
- Published
- 2009
27. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis
- Author
-
ANTONIO HERNANDO GRANDE, Federico Pulido, Enrique Bernal Morell, ANTONIO OCAMPO HERMIDA, Anna Bonjoch, Jose Molto, Vicente Estrada, Juan González-García, Maria Luisa Montes, Vicente Boix, Esperanza Merino de Lucas, Juan Pasquau, Matilde Sanchez-Conde, Rafael Rubio García, Ana Milinkovic, Hernando Knobel, Jose Arribas, Mª Jesus Perez Elias, and Joaquín Portilla
- Subjects
Oncology ,medicine.medical_specialty ,Anti-HIV Agents ,Lopinavir/ritonavir ,HIV Infections ,Pyrimidinones ,Pharmacology ,Lopinavir ,law.invention ,Pharmacotherapy ,Randomized controlled trial ,Maintenance therapy ,immune system diseases ,law ,Internal medicine ,Drug Resistance, Viral ,Medicine ,Humans ,Pharmacology (medical) ,Adverse effect ,Ritonavir ,biology ,business.industry ,virus diseases ,Nucleosides ,Middle Aged ,biology.organism_classification ,Infectious Diseases ,Lentivirus ,Drug Therapy, Combination ,business ,medicine.drug - Abstract
The OK04 trial has shown that 48 weeks of lopinavir-ritonavir monotherapy with reintroduction of nucleosides as needed was noninferior to continuation of triple therapy with 2 nucleosides and lopinavir-ritonavir in patients with prior stable suppression. However, it is still uncertain if this experimental strategy can maintain suppression in the long term.Patients entered this noninferiority trial (upper limit 95% confidence interval: +12%) with no history of virological failure while receiving a protease inhibitor and receiving 2 nucleosides plus lopinavir/ritonavir, with HIV RNA50 copies per milliliter for more than 6 months. Primary end point was percent of patients without therapeutic failure, defined as confirmed HIV RNA500 copies per milliliter with exclusion of monotherapy patients who resuppressed to50 copies per milliliter after resuming baseline nucleosides, or loss to follow-up, or change of randomized therapy other than reinduction.Through 96 weeks, percentage of patient without therapeutic failure was 87% (monotherapy, n = 100) vs. 78% (triple therapy, n = 98; 95% confidence interval: -20% to +1.2%). Percentage with HIV RNA50 copies per milliliter (intention to treat, missing = failure, reinduction = failure): 77% (monotherapy) vs. 78% (triple therapy). Low-level viral rebound was more frequent in the monotherapy group. Twelve patients in the monotherapy group (12%) needed reinduction with nucleosides. Discontinuations due to adverse events were significantly more frequent in the triple therapy group (8%) than in the monotherapy group (0%); P = 0.003.At 96-week lopinavir/ritonavir monotherapy with reintroduction of nucleosides as needed was noninferior to continuation of triple therapy. Incidence of adverse events leading to treatment discontinuation was significantly lower with monotherapy. (ClinicalTrials.gov number, NCT00114933).
- Published
- 2009
28. Effect of linagliptin on glucose metabolism and pancreatic beta cell function in patients with persistent prediabetes after metformin and lifestyle
- Author
-
Mildred Fátima de la Luz Alvarez-Canales, Sara Stephania Salazar-López, Diana Farfán-Vázquez, Yosceline Estrella Martínez-López, Jessica Noemí González-Mena, Lilia Marisela Jiménez-Ceja, Katya Vargas-Ortiz, María Lola Evia-Viscarra, María Luisa Montes de Oca-Loyola, Franco Folli, Alberto Aguilar-García, and Rodolfo Guardado-Mendoza
- Subjects
Medicine ,Science - Abstract
Abstract The goal of the study was to evaluate the effect of adding linagliptin to metformin and lifestyle on glucose levels and pancreatic β-cell function in patients with persistent impaired glucose tolerance (IGT) after 12 months of metformin and lifestyle. A single center parallel double-blind randomized clinical trial with 6 months of follow-up was performed in patients with persistent IGT after 12 months of treatment with metformin and lifestyle; patients were randomized to continue with metformin 850 mg twice daily (M group, n = 12) or linagliptin/metformin 2.5/850 mg twice daily (LM group, n = 19). Anthropometric measurements were obtained by standard methods and by bioelectrical impedance; glucose was measured by dry chemistry, insulin by chemiluminescence, and pancreatic β-cell function was calculated with the disposition index using glucose and insulin values during oral glucose tolerance test (OGTT) and adjusting by insulin sensitivity. The main outcomes were glucose levels during OGTT and pancreatic β-cell function. Patients in the LM group had a reduction in weight (−1.7 ± 0.6, p
- Published
- 2021
- Full Text
- View/download PDF
29. Patients' perception and effectiveness of a treatment containing enfuvirtide when used in HIV-infected patients without very advanced disease
- Author
-
Federico Pulido, Víctor Asensi Álvarez, Paloma Gijon, Juan M. García-Lechuz, Concepción Cepeda, Vicente Estrada, Juan González-García, Maria Luisa Montes, José A. Oteo, Asuncion Hernando, Jose Luis Casado, Jose Arribas, and Gabriel Gaspar Alonso-Vega
- Subjects
Adult ,Male ,medicine.medical_specialty ,Enfuvirtide ,HIV Infections ,Patient satisfaction ,HIV Fusion Inhibitors ,Internal medicine ,Surveys and Questionnaires ,Advanced disease ,medicine ,Hiv infected patients ,Humans ,Pharmacology (medical) ,business.industry ,Middle Aged ,Viral Load ,HIV Envelope Protein gp41 ,Peptide Fragments ,CD4 Lymphocyte Count ,Infectious Diseases ,Patient perceptions ,Cross-Sectional Studies ,Treatment Outcome ,Patient Satisfaction ,Baseline characteristics ,Physical therapy ,Quality of Life ,Patient Compliance ,Observational study ,Female ,business ,Viral load ,medicine.drug - Abstract
To evaluate the satisfaction with self-injected enfuvirtide (ENF) and the clinical outcome of HIV-infected patients without very advanced disease.ESPPE is a multicenter observational study that included 103 evaluated patients showing baseline characteristics predictive of positive outcome: CD4100 cells/mm3, viral load (VL)100,000 copies/mL, previous treatment with a maximum of 10 antiretroviral drugs, and concomitant use of 2 active drugs. By using validated surveys, patients were questioned 6 months after the prescription of ENF about their quality of life (QoL) and acceptance of self-injections and adherence to the treatment.At 6 months, the mean CD4 increase was 121 cells/mm3 (p.05) and 65% (intent-to-treat, ENF stopped=failure) had VL50 copies/mL (p.001). Fourteen patients discontinued the treatment, mostly due to intolerance (6). The majority (89%) assessed all items relating QoL as "excellent," "very good," or "good." The treatment satisfaction index on a visual analog scale scored a median of 8.1 out of 10; when participants were asked about the interference of injections on their daily activities, 87% answered "never" or "only sometimes."Effectiveness and patients' perception about ENF remain good when ENF was used in patients without very advanced disease. QoL was not impaired after ENF use.
- Published
- 2008
30. Repuesta
- Author
-
Jose Francisco Pascual Pareja, Maria Luisa Montes, Juan González-García, and Jose Arribas
- Subjects
General Medicine - Published
- 2010
31. Tuberculosis Complicating Hepatitis C Treatment in HIV‐Infected Patients
- Author
-
Pérez‐Elías, Maria Jesús, primary, Miguel, Lucía García‐San, additional, García, Juan González, additional, Ramírez, Maria Luisa Montes, additional, Muriel, Alfonso, additional, Machín‐Lázaro, Jose M., additional, Martínez‐Baltanás, Aida, additional, Zamora, Francisco, additional, Moreno, Ana, additional, Martín‐Dávila, Pilar, additional, Quereda, Carmen, additional, Gómez‐Mampaso, Enrique, additional, and Moreno, Santiago, additional
- Published
- 2009
- Full Text
- View/download PDF
32. Psoriasis and Liver Damage in HIV-Infected Patients
- Author
-
Carmen Busca Arenzana, Lucía Quintana Castanedo, Clara Chiloeches Fernández, Daniel Nieto Rodríguez, Pedro Herranz Pinto, Ana Belén Delgado Hierro, Antonio Olveira Martín, and María Luisa Montes Ramírez
- Subjects
psoriasis ,HIV ,NAFLD ,liver fibrosis ,Cytology ,QH573-671 - Abstract
Background/objectives: Psoriasis is the most frequent skin disease in HIV-infected patients. Nonalcohol fatty liver disease (NAFLD) is more prevalent in patients with psoriasis. We report the prevalence of psoriasis and NAFLD and investigate risk factors of liver damage in HIV-infected patients with psoriasis. Methods: We performed a retrospective observational study. Steatosis was defined as indicative abdominal ultrasound findings, CAP (controlled attenuated parameter by transient elastography) > 238 dB/m, and/or triglyceride and glucose index (TyG) > 8.38. Significant (fibrosis ≥ 2) and advanced liver fibrosis (fibrosis ≤ F3) were studied by transient elastography (TE) and/or FIB-4 using standard cutoff points. FIB-4 (Fibrosis 4 score) results were adjusted for hepatitis C (HCV)-coinfected patients. Results: We identified 80 patients with psoriasis (prevalence, 1.5%; 95% CI, 1.1–1.8). Psoriasis was severe (PASI > 10 and/or psoriatic arthritis) in 27.5% of cases. The prevalence of steatosis was 72.5% (95% CI, 65–85). Severe psoriasis was an independent risk factor for steatosis (OR, 12; 95% CI, 1.2–120; p = 0.03). Significant liver fibrosis (p < 0.05) was associated with HCV coinfection (OR 3.4; 95% CI, 1.1–10.6), total CD4 (OR 0.99; 95% CI, 0.99–1), and time of efavirenz exposure (OR 1.2; 95% CI, 1.0–1.3). Conclusions: The prevalence of psoriasis in HIV-infected patients was similar to that of the general population. Steatosis is highly prevalent, and severe psoriasis is an independent risk factor for steatosis in HIV-infected patients.
- Published
- 2021
- Full Text
- View/download PDF
33. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
- Author
-
Maria Luisa Montes, Federico Pulido, Carlos Barros, Emilia Condes, Rafael Rubio, Concepcin Cepeda, Fernando Dronda, Antonio Antela, Jos Sanz, Enrique Navas, Pilar Miralles, Juan Berenguer, Susana Prez, Angeles Zapata, Juan J. Gonzlez-Garca, Jose Ma Pea, J. J. Vzquez, and Jose R. Arribas
- Subjects
LIPIDS ,HEPATITIS C ,VIRAL hepatitis ,ANTIRETROVIRAL agents - Abstract
Objectives: The aim of this study was to evaluate the frequency, characteristics and risk factors of lipid changes associated with lopinavir/ritonavir treatment in antiretroviral-naive patients.Methods: A prospective cohort of 107 antiretroviral-naive HIV-infected patients was followed for 12 months after starting lopinavir/ritonavir-based highly active antiretroviral therapy.Results: At 12 months, percentages of patients with hypercholesterolaemia and hypertriglyceridaemia were 17.4% and 40%, respectively. Mean increases in total cholesterol and triglycerides were 40.7 and 73.3?mg/dL. There was a significant increase in both low-density and high-density (HDL) cholesterol, and no increase in the total cholesterol/HDL ratio (from 4.16 at baseline to 4.49 after 12 months). Baseline cholesterol >?200?mg/dL and triglycerides >?150?mg/dL were independent risk factors for dyslipidaemia, while hepatitis C coinfection appeared to be protective.Conclusions: Patients with elevated lipid values at baseline have the greatest risk of developing hypercholesterolaemia and hypertriglyceridaemia after starting lopinavir/ritonavir. Antiretroviral-naive patients coinfected with hepatitis C have a low risk of developing hyperlipidaemia after starting lopinavir/ritonavir. [ABSTRACT FROM AUTHOR]
- Published
- 2005
- Full Text
- View/download PDF
34. Spatiotemporal Characteristics of the Largest HIV-1 CRF02_AG Outbreak in Spain: Evidence for Onward Transmissions
- Author
-
Evangelia-Georgia Kostaki, Andreas Flampouris, Timokratis Karamitros, Natalia Chueca, Marta Alvarez, Paz Casas, Belen Alejos, Angelos Hatzakis, Federico Garcia, Dimitrios Paraskevis, CoRIS, Santiago Moreno, Inma Jarrín, David Dalmau, Maria Luisa Navarro, Maria Isabel González, Jose Luis Blanco, Rafael Rubio, Jose Antonio Iribarren, Félix Gutiérrez, Francesc Vidal, Juan Berenguer, Juan González, Belén Alejos, Victoria Hernando, Cristina Moreno, Carlos Iniesta, Luis Miguel Garcia Sousa, Nieves Sanz Perez, M Ángeles Muñoz-Fernández, Isabel María García-Merino, Irene Consuegra Fernández, Coral Gómez Rico, Jorge Gallego de la Fuente, Paula Palau Concejo, Joaquín Portilla, Esperanza Merino, Sergio Reus, Vicente Boix, Livia Giner, Carmen Gadea, Irene Portilla, María Pampliega, Marcos Díez, Juan Carlos Rodríguez, José Sánchez-Payá, Juan Luis Gómez, Jehovana Hernández, María Remedios Alemán, María del Mar Alonso, María Inmaculada Hernández, Felicitas Díaz-Flores, Dácil García, Ricardo Pelazas, Ana López Lirola, José Sanz Moreno, Alberto Arranz Caso, Cristina Hernández Gutiérrez, María Novella Mena, Federico Pulido, Otilia Bisbal, Asunción Hernando, Lourdes Domínguez, David Rial Crestelo, Laura Bermejo, Mireia Santacreu, José Antonio Iribarren, Julio Arrizabalaga, María José Aramburu, Xabier Camino, Francisco Rodríguez-Arrondo, Miguel Ángel von Wichmann, Lidia Pascual Tomé, Miguel Ángel Goenaga, Ma Jesús Bustinduy, Harkaitz Azkune, Maialen Ibarguren, Aitziber Lizardi, Xabier Kortajarena, Mar Masiá, Sergio Padilla, Andrés Navarro, Fernando Montolio, Catalina Robledano, Joan Gregori Colomé, Araceli Adsuar, Rafael Pascual, Marta Fernández, Elena García, José Alberto García, Xavier Barber, Juan Carlos López Bernaldo de Quirós, Isabel Gutiérrez, Margarita Ramírez, Belén Padilla, Paloma Gijón, Teresa Aldamiz-Echevarría, Francisco Tejerina, Francisco José Parras, Pascual Balsalobre, Cristina Diez, Leire Pérez Latorre, Joaquín Peraire, Consuelo Viladés, Sergio Veloso, Montserrat Vargas, Miguel López-Dupla, Montserrat Olona, Anna Rull, Esther Rodríguez-Gallego, Verónica Alba, Marta Montero Alonso, José López Aldeguer, Marino Blanes Juliá, María Tasias Pitarch, Iván Castro Hernández, Eva Calabuig Muñoz, Sandra Cuéllar Tovar, Miguel Salavert Lletí, Juan Fernández Navarro, Jose Miguel Molina, Juan González-garcia, Francisco Arnalich, José Ramón Arribas, Jose Ignacio Bernardino de la Serna, Juan Miguel Castro, Luis Escosa, Pedro Herranz, Victor Hontañón, Silvia García-Bujalance, Milagros García López-Hortelano, Alicia González-Baeza, Maria Luz Martín-Carbonero, Mario Mayoral, Maria Jose Mellado, Rafael Esteban Micán, Rocio Montejano, María Luisa Montes, Victoria Moreno, Ignacio Pérez-Valero, Berta Rodés, Talia Sainz, Elena Sendagorta, Natalia Stella Alcáriz, Eulalia Valencia, José Ramón Blanco, José Antonio Oteo, Valvanera Ibarra, Luis Metola, Mercedes Sanz, Laura Pérez-Martínez, Angels Jaén, Montse Sanmartí, Mireia Cairó, Javier Martinez-Lacasa, Pablo Velli, Roser Font, Mariona Xercavins, Noemí Alonso, Jesús Repáraz, María Gracia Ruiz de Alda, María Teresa de León Cano, Beatriz Pierola Ruiz de Galarreta, Ignacio de los Santos, Jesús Sanz Sanz, Ana Salas Aparicio, Cristina Sarriá Cepeda, Lucio Garcia-Fraile Fraile, Enrique Martín Gayo, José Luis Casado, Fernando Dronda, Ana Moreno, María Jesús Pérez Elías, Cristina Gómez Ayerbe, Carolina Gutiérrez, Nadia Madrid, Santos del Campo Terrón, Paloma Martí, Uxua Ansa, Sergio Serrano, María Jesús Vivancos, Enrique Bernal, Alfredo Cano, Antonia Alcaraz García, Joaquín Bravo Urbieta, Ángeles Muñoz, Maria Jose Alcaraz, Maria del Carmen Villalba, Federico García, José Hernández, Alejandro Peña, Leopoldo Muñoz, David Vinuesa, Clara Martinez-Montes, Fernando García, Carlos Guerrero-Beltran, Jorge Del Romero, Carmen Rodríguez, Teresa Puerta, Juan Carlos Carrió, Mar Vera, Juan Ballesteros, Oskar Ayerdi, Antonio Antela, Elena Losada, Antonio Aguilera, Melchor Riera, María Peñaranda, María Leyes, Ma Angels Ribas, Antoni A Campins, Carmen Vidal, Francisco Fanjul, Javier Murillas, Francisco Homar, Jesús Santos, Crisitina Gómez Ayerbe, Isabel Viciana, Rosario Palacios, Carmen María González, Pompeyo Viciana, Nuria Espinosa, Luis Fernando López-Cortés, Daniel Podzamczer, Elena Ferrer, Arkaitz Imaz, Juan Tiraboschi, Ana Silva, María Saumoy, Julián Olalla, Alfonso del Arco, Javier de la torre, José Luis Prada, José María García de Lomas Guerrero, Javier Pérez Stachowski, Concepción Amador, Onofre Juan Martínez, Francisco Jesús Vera, Lorena Martínez, Josefina García, Begoña Alcaraz, Amaya Jimeno, Angeles Castro Iglesias, Berta Pernas Souto, Alvaro Mena de Cea, Carlos Galera, Helena Albendin, Aurora Pérez, Asunción Iborra, Antonio Moreno, Maria Angustias Merlos, Asunción Vidal, Inés Suárez-García, Eduardo Malmierca, Patricia González-Ruano, Dolores Martín Rodrigo, Mohamed Omar Mohamed-Balghata, Juan A Pineda, Juan Macías, Miguel Thomson, Elena Delgado, Sonia Benito, and Vanessa Montero
- Subjects
HIV-1 ,CRF02_AG ,Spain ,regional dispersal ,spatiotemporal characteristics ,Microbiology ,QR1-502 - Abstract
Background and Aim: The circulating recombinant form 02_AG (CRF02_AG) is the predominant clade among the human immunodeficiency virus type-1 (HIV-1) non-Bs with a prevalence of 5.97% (95% Confidence Interval-CI: 5.41–6.57%) across Spain. Our aim was to estimate the levels of regional clustering for CRF02_AG and the spatiotemporal characteristics of the largest CRF02_AG subepidemic in Spain.Methods: We studied 396 CRF02_AG sequences obtained from HIV-1 diagnosed patients during 2000–2014 from 10 autonomous communities of Spain. Phylogenetic analysis was performed on the 391 CRF02_AG sequences along with all globally sampled CRF02_AG sequences (N = 3,302) as references. Phylodynamic and phylogeographic analysis was performed to the largest CRF02_AG monophyletic cluster by a Bayesian method in BEAST v1.8.0 and by reconstructing ancestral states using the criterion of parsimony in Mesquite v3.4, respectively.Results: The HIV-1 CRF02_AG prevalence differed across Spanish autonomous communities we sampled from (p < 0.001). Phylogenetic analysis revealed that 52.7% of the CRF02_AG sequences formed 56 monophyletic clusters, with a range of 2–79 sequences. The CRF02_AG regional dispersal differed across Spain (p = 0.003), as suggested by monophyletic clustering. For the largest monophyletic cluster (subepidemic) (N = 79), 49.4% of the clustered sequences originated from Madrid, while most sequences (51.9%) had been obtained from men having sex with men (MSM). Molecular clock analysis suggested that the origin (tMRCA) of the CRF02_AG subepidemic was in 2002 (median estimate; 95% Highest Posterior Density-HPD interval: 1999–2004). Additionally, we found significant clustering within the CRF02_AG subepidemic according to the ethnic origin.Conclusion: CRF02_AG has been introduced as a result of multiple introductions in Spain, following regional dispersal in several cases. We showed that CRF02_AG transmissions were mostly due to regional dispersal in Spain. The hot-spot for the largest CRF02_AG regional subepidemic in Spain was in Madrid associated with MSM transmission risk group. The existence of subepidemics suggest that several spillovers occurred from Madrid to other areas. CRF02_AG sequences from Hispanics were clustered in a separate subclade suggesting no linkage between the local and Hispanic subepidemics.
- Published
- 2019
- Full Text
- View/download PDF
35. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
- Author
-
María-Carlota Londoño, Mar Riveiro-Barciela, Adriana Ahumada, Raquel Muñoz-Gómez, Mercé Roget, María J Devesa-Medina, Miguel Ángel Serra, Carmen A Navascués, Carme Baliellas, Teresa Aldamiz-Echevarría, María L Gutiérrez, Benjamín Polo-Lorduy, Isabel Carmona, Salvador Benlloch, Lucía Bonet, Javier García-Samaniego, Miguel Jiménez-Pérez, Senador Morán-Sánchez, Ángeles Castro, Manuel Delgado, Francisco Gea-Rodríguez, Ignacio Martín-Granizo, María Luisa Montes, Luís Morano, Manuel A Castaño, Ignacio de Los Santos, Montserrat Laguno, Juan Emilio Losa, Marta Montero-Alonso, Antonio Rivero, Cristina de Álvaro, Amanda Manzanares, Josep Mallolas, Guillermina Barril, Emilio González-Parra, and Luisa García-Buey
- Subjects
Medicine ,Science - Abstract
Background and aimsLimited data are available on the effectiveness and tolerability of direct-acting antivirals (DAAs) therapies in the real world for HCV-infected patients with comorbidities. This study aimed to describe the effectiveness of OBV/PTV/r ± DSV (3D/2D regimen) with or without ribavirin (RBV) in HCV or HCV/HIV co-infected patients with GT1/GT4 and CKD (IIIb-V stages), including those under hemodialysis and peritoneal dialysis in routine clinical practice in Spain in 2015.Material and methodsNon-interventional, retrospective, multicenter data collection study in 31 Spanish sites. Socio-demographic, clinical variables, study treatment characteristics, effectiveness and tolerability data were collected from medical records.ResultsData from 135 patients with a mean age (SD) of 58.3 (11.4) years were analyzed: 92.6% GT1 (81.6% GT1b and 17.6% GT1a) and 7.4% GT4, 14 (10.4%) HIV/HCV co-infected, 19.0% with fibrosis F3 and 28.1% F4 by FibroScan®, 52.6% were previously treated with pegIFN and RBV. 11.1%, 14.8% and 74.1% of patients had CKD stage IIIb, IV and V respectively. 68.9% of patients were on hemodialysis; 8.9% on peritoneal dialysis and 38.5% had history of renal transplant. A total of 125 (96.2%) of 135 patients were treated with 3D, 10 (7.4%) with 2D and 30.4% received RBV. The overall intention-to-treat (ITT) sustained virologic response at week 12 (SVR12) was 92.6% (125/135) and the overall modified-ITT (mITT) SVR12 was 99.2% (125/126). The SVR12 rates (ITT) per sub-groups were: HCV mono-infected (91.7%), HCV/HIV co-infected (100%), GT1 (92.0%), GT4 (100%), CKD stage IIIb (86.7%), stage IV (95%) and stage V (93%). Among the 10 non-SVR there was only 1 virologic failure (0.7%); 4 patients had missing data due lost to follow up (3.0%) and 5 patients discontinued 3D/2D regimen (3.7%): 4 due to severe adverse events (including 3 deaths) and 1 patient´s decision.ConclusionsThese results have shown that 3D/2D regimens are effective and tolerable in patients with advanced CKD including those in dialysis with GT 1 or 4 chronic HCV mono-infection and HIV/HCV coinfection in a real-life cohort. The overall SVR12 rates were 92.6% (ITT) and 99.2% (mITT) without clinically relevant changes in eGFR until 12 weeks post-treatment. These results are consistent with those reported in clinical trials.
- Published
- 2019
- Full Text
- View/download PDF
36. High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir/ritonavir monotherapy: A randomized clinical trial.
- Author
-
Juan Pasquau, Carmen Hidalgo-Tenorio, María Luisa Montes, Alberto Romero-Palacios, Jorge Vergas, Isabel Sanjoaquín, José Hernández-Quero, Koldo Aguirrebengoa, Francisco Orihuela, Arkaitz Imaz, María José Ríos-Villegas, Juan Flores, María Carmen Fariñas, Pilar Vázquez, María José Galindo, Isabel García-Mercé, Fernando Lozano, Ignacio de Los Santos, Samantha Elizabeth de Jesus, Coral García-Vallecillos, and QoLKAMON STUDY GROUP
- Subjects
Medicine ,Science - Abstract
The QoLKAMON study evaluated quality of life, efficacy and treatment safety in HIV patients receiving lopinavir/ritonavir in monotherapy (MT) versus continuing combined antiretroviral triple treatment with a boosted protease inhibitor (TT).This was a 24-week, open-label, multicentre study in virologically-suppressed HIV-infected participants (N = 225) with a 2:1 randomization: 146 patients who switched to MT were compared with 79 patients who remained on a TT regimen. The primary endpoint was change in patient-reported outcomes in quality of life as measured by the MOS-HIV and EQ-5D questionnaires. Secondary endpoints included treatment adherence, patient satisfaction, incidence of adverse events and differences in plasma HIV-1 RNA viral load (VL) and CD4 cell counts.Baseline quality of life, measured with the MOS-HIV score, was very good (overall score of 83 ± 10.5 in the MT arm and 82.3 ± 11.3 in the TT arm) and suffered no change during the study in any of the arms (at week 24, 83.5 ± 12.2 in MT arm and 81.9 ± 12.7 in TT arm), without statistically significant differences when compared. In regards to adherence to therapy and patient satisfaction, some aspects (number of doses forgotten in the last week and satisfaction of treatment measured with the CESTA score, dimension 1) improved significantly with MT. There were also no differences in the incidence and severity of adverse events, even though 22.8% of those in the MT arm switched their treatment when they were included in the study. Moreover, there was also no significant difference between the immunological and virological evolution of MT and TT. In the MT arm, the VL was always undetectable in 83% of patients (vs 90.7% in the TT arm) and there were only 6.7% of virological failures with VL > 50 copies/mL (vs 2.3% in the TT arm), without resistance mutations and with resuppression of VL after switching back to TT.In a new clinical trial, monotherapy as a treatment simplification strategy in HIV-1 infected patients with sustained viral suppression has demonstrated quality of life, safety and efficacy profiles comparable to those of conventional triple therapy regimens.
- Published
- 2018
- Full Text
- View/download PDF
37. Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004–2013
- Author
-
Consuelo Viladés, Nuria Espinosa, VERONICA ALBA ELVIRA, Federico Pulido, Eva Calabuig, Jose-Ramon Blanco, Miriam Estebanez, Sergio Veloso Esteban, Julia Del amo, Pablo Barreiro, Víctor Asensi Álvarez, INMA JARRIN, Andrés Navarro Ruiz, Ignacio De Los Santos Gil, Cairó Mireia, VICTORIA HERNANDO, Enrique Bernal Morell, Paloma Gijon, Mar Masiá, Roberto Muga, Mariona Xercavins, Livia Giner, Laura Ibanez, LUZ MARTÍN CARBONERO, Francesc Vidal, DAVID DALMAU, Vicente Soriano, Montserrat Vargas Laguna, JUAN JOSE SIRVENT, Jesús Miguel López Dupla, Juan González-García, Mar Vera, Maria Luisa Montes, José A. Oteo, Maria Jose Amengual, MARIA PEÑARANDA VERA, Vicente Boix, Maria-Mercedes Nogueras, Marta Montero, Sergio Padilla, Mª Ángeles Muñoz-Fernández, Angeles Jaen, Natalia Chueca, José Ignacio Bernardino, Luis Fernando Lopez.Cortes, Jesus Mingorance, Rafael Rubio García, Félix Gutiérrez, Eulalia Valle-Garay, Ana Gomez-Berrocal, Asuncion Hernando, RICARDO PELAZAS GONZÁLEZ, Cristina Gonzalez, Jose Luis Casado, Jose Arribas, Francisco J Blanco Garcia, Mª Jesus Perez Elias, Joaquín Portilla, Instituto de Salud Carlos III, and Unión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF)
- Subjects
0301 basic medicine ,Microbiology (medical) ,Adult ,Male ,medicine.medical_specialty ,Delayed Diagnosis ,Human immunodeficiency virus (HIV) ,HIV Infections ,medicine.disease_cause ,Logistic regression ,Cohort Studies ,03 medical and health sciences ,0302 clinical medicine ,Acquired immunodeficiency syndrome (AIDS) ,Risk Factors ,Internal medicine ,Cause of Death ,medicine ,Humans ,030212 general & internal medicine ,Mortality ,Causes of death ,Survival analysis ,Cause of death ,Aged ,business.industry ,Proportional hazards model ,HIV ,Middle Aged ,medicine.disease ,030112 virology ,Survival Analysis ,Late presentation ,Infectious Diseases ,Spain ,Immunology ,Cohort ,Female ,business ,Factors and trends ,Cohort study - Abstract
To analyze the impact of late presentation (LP) on overall mortality and causes of death and describe LP trends and risk factors (2004-2013). Cox models and logistic regression were used to analyze data from a nation-wide cohort in Spain. LP is defined as being diagnosed when CD4 4 years, aHRLP.vs.nLP = 1.5(0.7-3.1). First-year's main cause of death was HIV/AIDS (73%); and malignancies among those surviving >4 years (32%). HIV/AIDS-related deaths were more likely in LP (59.2% vs. 25.0%; p 50.vs.
- Full Text
- View/download PDF
38. High presence of HCV genotype 4d in HIV/HCV co-infected HIV / HCV patients in Espana.LOST G4
- Author
-
Ortega Gonzalez, Enrique, Wichmann, Miguel A., Alma Bracho, Maria, Asensi, Victor, Antonio Mira, Jose, Granados, Rafael, Maria Luisa Montes, Giner, Livia, Martin, Carlos, Rivero-Juarez, Antonio, Arnaiz Las Revillas, Francisco, Berenguer, Juan, Tural, Cristina, Vera, Francisco, Luis Gomez-Sirvent, Juan, Antonio Oteo, Jose, Martinez, Elisa, Aguilera, Antonio, Morano, Luis, Navarro, Jorge, Oropesa, Roberto, Moreno, Javier, and Rubio-Cuevas, Purificacion
39. Real-world Outcomes With New HCV Antivirals in HIV/HCV-coinfected Subjects: Madrid Coinfection Registry (Madrid-CoRE) Findings
- Author
-
Gil-Martin, Angela, Gonzalez-Garcia, Juan J., Cruz-Martos, Encarnacion, Moreno, Ana, Dominguez-Dominguez, Lourdes, Maria Luisa Montes, Aldamiz-Echevarria, Teresa, Tellez, Maria J., Los Santos, Ignacio, Benitez, Laura, Sanz, Jose, Ryan, Pablo, Gaspar, Gabriel, Gorgolas, Miguel, Losa, Juan E., Torres-Perea, Rafael, Barros, Carlos, Victor San Martin, Juan, Arponen, Sari, Jose Calvo, Maria, Alcaraz, Marta, Jarrin, Inmaculada, and Berenguer, Juan
40. Central nervous system penetration and effectiveness of darunavir/ritonavir monotherapy
- Author
-
Perez Valero, Ignacio, Gonzalez-Baeza, Alicia, and Maria Luisa Montes
41. Correlation between blood telomere length and CD4(+) CD8(+) T-cell subsets in HIV-1-positive individuals with long-term virological suppression on antiretroviral therapy
- Author
-
Rodriguez-Centeno, J., Esteban-Cantos, A., Stella-Ascariz, N., Montejano, R., Miguel, R., Alejos, B., Mena-Garay, B., Rodes, B., Bernardino, J. I., Castro, J. M., Mayoral, M., Perez-Valero, I., Maria Luisa Montes, Valencia, E., Martin-Carbonero, L., Moreno, V., Cadinanos, J., Gonzalez-Garcia, J., Arnalich, F., and Arribas, J. R.
42. Effect of mono/dual antiretroviral therapy on HCV and HIV suppression during HCV treatment in HIV/HCV co-infected patients
- Author
-
Martin-Carbonero, Luz, Dominguez, Lourdes, Bailon, Lucia, Torres, Rafael, Rubio, Rafael, Ron, Raquel, Rico, Mikel, Jimenez-Nacher, Inmaculada, Moreno, Francisco, Gonzalez, Juan, Pulido, Federico, and Maria Luisa Montes
43. Efficacy and safety of telaprevir based triple therapy in coinfected patients with advanced fibrosis. Final results of the spanish cohort
- Author
-
Wichmann, Miguel A., Moreno, Ana, Lopez Cortes, Luis F., Ortega, Enrique, Mira, Jose Antonio, Quereda, Carmen, Maria Luisa Montes, Tellez, Maria, Garcia Del Toro, Miguel, Iribarren, Jose A., Camacho, Angela M., Martin-Carbonero, Luz, Portu, Joseba, Blanco, Jose-Ramon, Aguirrebengoa, Koldo, Berenguer, Juan, Gonzalez Garcia, Juan, and Marquez Solero, Manuel
44. Efficacy and safety of therapy with Telaprevir (DAA) in genotype 1 coinfected patients with advanced fibrosis. Six month follow-up data
- Author
-
Wichmann, Miguel A., Moreno, Ana, Ortega, Enrique, Antonio Mira, Jose, Maria Luisa Montes, Tellez, Maria J., Quereda, Carmen, Iribarren, Jose A., Garcia Deltoro, Miguel, Marquez Solero, Manuel, Portu, Joseba, Gonzalez-Garcia, Juan J., Aguirrebengoa, Koldo, Blanco, Jose-Ramon, Berenguer, Juan, Lopez Cortes, Luis F., and Camacho, Angela M.
45. Reproducibility of the circadian blood pressure pattern in HIV infected patients using ambulatory blood pressure monitoring (ABPM)
- Author
-
Bernardino, J. I., Mohr, R., Pena, J. M., Zamora, F. X., Perez-Valero, I., Gonzalez, J., Maria Luisa Montes, Serrano, L., and Arribas, J. R.
46. Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain.
- Author
-
Deanna Kerrigan, Andrea Mantsios, Miguel Gorgolas, Maria-Luisa Montes, Federico Pulido, Cynthia Brinson, Jerome deVente, Gary J Richmond, Sarah W Beckham, Paige Hammond, David Margolis, and Miranda Murray
- Subjects
Medicine ,Science - Abstract
Challenges with adherence to daily oral antiretroviral therapy (ART) among people living with HIV (PLHIV) have stimulated development of injectable long-acting (LA) regimens. We conducted 39 in-depth interviews with participants and providers in a Phase IIb study (LATTE-2) evaluating an injectable LA regimen in the U.S. and Spain. Interviews exploring participant and provider attitudes and experiences with LA versus oral ART were audiotaped, transcribed and analyzed using thematic content analysis. Participants described the convenience of LA injections versus daily pills and emotional benefits such as minimized potential for HIV disclosure and eliminating the "daily reminder of living with HIV." Providers recognized benefits but cautioned that LA candidates still need to adhere to clinic visits for injections and raised questions around ongoing clinical management. LA was seen as preferable to daily oral ART among PLHIV. Further research is needed regarding appropriate candidates, including with women and "non-adherent" populations across settings.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.